EG
Elite in Metastatic Brain Tumor
Check Dr. Elizabeth R. Gerstner's experience treating your condition:
About Dr. Elizabeth R. Gerstner

Elizabeth Gerstner is a Neurologist in Boston, Massachusetts. Gerstner has been practicing medicine for over 21 years and is rated as an Elite expert by MediFind in the treatment of Metastatic Brain Tumor. She is also highly rated in 18 other conditions, according to our data. Her top areas of expertise are Glioblastoma, Astrocytoma, Glioma, Brain Tumor, and Awake Craniotomy. She is licensed to treat patients in Massachusetts. Gerstner is currently accepting new patients.

Her clinical research consists of co-authoring 118 peer reviewed articles and participating in 15 clinical trials in the past 15 years. In particular, she has co-authored 9 articles and participated in 1 clinical trial in the study of Metastatic Brain Tumor.

Insurance

MediFind strives to display the most accurate insurance information for every doctor. If you do not see your insurance listed for Dr. Elizabeth R. Gerstner it is best to call her office and ask if your insurance is accepted.

Accepts Medicare

Call to see if your plan is accepted.
Locations
55 Fruit St, Boston, MA 02114
Background & Education
Graduate Institution
Columbia University College Of Physicians And Surgeons, 2002
Specialties
Neurology
Licenses
Psychiatry & Neurology in MA
Hospital Affiliations
Brigham And Womens Hospital
Massachusetts General Hospital
Dana Farber Cancer Institute
North Shore Medical Center - Salem Hospital
Massachusetts Eye And Ear
Languages Spoken
English
Spanish
Gender
Female
Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Doctors who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


15 Clinical Trials

Phase II Trial of BRAF/MEK Inhibitors in Papillary Craniopharyngiomas
Phase II Trial of SMO/ AKT/ NF2/CDK Inhibitors in Progressive Meningiomas With SMO/ AKT/ NF2/CDK Pathway Mutations
Advanced MRI Applications Development
A Phase I Trial of Anti-LAG-3 or Anti-CD137 Alone and in Combination With Anti-PD-1 in Patients With Recurrent GBM
Phase I Study of Neoadjuvant GMCI Plus Immune Checkpoint Inhibitor Combined With Standard of Care for Newly Diagnosed High-Grade Gliomas
Phase II Clinical Trial of Bavituximab With Radiation and Temozolomide for Patients With Newly Diagnosed Glioblastoma
A Study to Evaluate Vascular Normalization in Patients With Recurrent Glioblastoma Treated With Bevacizumab Using FMISO PET and Vascular MRI
A Study to Evaluate Vascular Normalization in Patients With Recurrent Glioblastoma Treated With Bevacizumab Using [11C]Temozolomide PET and Vascular MRI
Quantitative Assessment of the Early and Late Effects of Radiation and Chemotherapy on Glioblastoma Using Multiple MRI Techniques
A Pilot Study to Evaluate PBR PET in Brain Tumor Patients Treated With Chemoradiation or Immunotherapy
Multicenter, Phase II Assessment of Tumor Hypoxia in Glioblastoma Using 18F-Fluoromisonidazole (FMISO) With PET and MRI
A Phase II Study of Tivozanib in Recurrent Glioblastoma
A Phase Ib Study of Cediranib in Combination With Cilengitide in Patients With Recurrent Glioblastoma
A Pilot Study to Evaluate Tumor Pseudoprogression With FLT-PET and MRI
View 12 Less Clinical Trials -

118 Total Publications

Alliance A071401: Phase II Trial of Focal Adhesion Kinase Inhibition in Meningiomas With Somatic NF2 Mutations.


Save this doctor for later
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find a second opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn more
Similar Doctors
Elite
Elite
Elite